Evidence map›Paper›PMID 34462750›Full record

ArticlebioRxiv : the preprint server for biology2021

The B.1.427/1.429 (epsilon) SARS-CoV-2 variants are more virulent than ancestral B.1 (614G) in Syrian hamsters.

Timothy Carroll, Douglas Fox, Neeltje van Doremalen, Erin Ball, Mary Kate Morris, Alicia Sotomayor-Gonzalez, Venice Servellita, Arjun Rustagi, Claude Kwe Yinda, Linda Fritts and 10 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 10 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 1 country.

Timothy CarrollCalifornia National Primate Research Center, University of California Davis, Davis CA, USA.
Douglas FoxUniversity of California, Berkeley, Department of Molecular and Cell Biology, Division of Immunology and Pathogenesis.
Neeltje van DoremalenLaboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.
Erin BallDepartment of Pathology, Microbiology and Immunology, School of Veterinary Medicine, University of California Davis, Davis CA, USA.
Mary Kate MorrisDivision of Viral and Rickettsial Diseases, California Department of Public Health, Richmond, CA, USA.
Alicia Sotomayor-GonzalezDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
Venice ServellitaDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
Arjun RustagiDivision of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine.
Claude Kwe YindaLaboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.
Linda FrittsCalifornia National Primate Research Center, University of California Davis, Davis CA, USA.
Julia Rebecca PortLaboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.
Zhong-Min MaCalifornia National Primate Research Center, University of California Davis, Davis CA, USA.
Myndi HolbrookLaboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.
Jonathan SchulzLaboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.
Catherine A BlishDivision of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine.
Carl HansonDivision of Viral and Rickettsial Diseases, California Department of Public Health, Richmond, CA, USA.
Charles Y ChiuDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
Vincent MunsterLaboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.
Sarah StanleyUniversity of California, Berkeley, Department of Molecular and Cell Biology, Division of Immunology and Pathogenesis.
Christopher J MillerCalifornia National Primate Research Center, University of California Davis, Davis CA, USA.
National Institutes of Health · USUniversity of California, Davis · USUniversity of California, San Francisco · USCalifornia Department of Public Health · USStanford University · USUniversity of California, Berkeley · US

Funding

Virus Ecology UnitZIAAI001179 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MUNSTER, VINCENT · 2013 to 2025
$24.3M
EMERGING INFECTIOUS DISEASEST32AI007502 · NIAID · STANFORD UNIVERSITY · PI Prasanna Jagannathan, DAVID A. RELMAN · 1995 to 2026
$6.8M
How did a vaccine enhance HIV acquisitionR01AI118590 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI MILLER, CHRISTOPHER JAMES · 2015 to 2019
$3.3M
Identification of diagnostic and prognostic host biomarkers of Zika virus infection by transcriptome profilingR21AI129455 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHIU, CHARLES YEN · 2017 to 2018
$436k
Intramural NIH HHS ZIA AI001179NIAID NIH HHS R01 AI118590NIAID NIH HHS R21 AI129455NIAID NIH HHS T32 AI007502
6 · The paper itself

Abstract

As novel SARS-CoV-2 variants continue to emerge, it is critical that their potential to cause severe disease and evade vaccine-induced immunity is rapidly assessed in humans and studied in animal models. In early January 2021, a novel variant of concern (VOC) designated B.1.429 comprising 2 lineages, B.1.427 and B.1.429, was originally detected in California (CA) and shown to enhance infectivity in vitro and decrease antibody neutralization by plasma from convalescent patients and vaccine recipients. Here we examine the virulence, transmissibility, and susceptibility to pre-existing immunity for B 1.427 and B 1.429 in the Syrian hamster model. We find that both strains exhibit enhanced virulence as measured by increased body weight loss compared to hamsters infected with ancestral B.1 (614G), with B.1.429 causing the most body weight loss among all 3 lineages. Faster dissemination from airways to parenchyma and more severe lung pathology at both early and late stages were also observed with B.1.429 infections relative to B.1. (614G) and B.1.427 infections. In addition, subgenomic viral RNA (sgRNA) levels were highest in oral swabs of hamsters infected with B.1.429, however sgRNA levels in lungs were similar in all three strains. This demonstrates that B.1.429 replicates to higher levels than ancestral B.1 (614G) or B.1.427 in the upper respiratory tract (URT) but not in the lungs. In multi-virus in-vivo competition experiments, we found that epsilon (B.1.427/B.1.429) and gamma (P.1) dramatically outcompete alpha (B.1.1.7), beta (B.1.351) and zeta (P.2) in the lungs. In the URT gamma, and epsilon dominate, but the highly infectious alpha variant also maintains a moderate size niche. We did not observe significant differences in airborne transmission efficiency among the B.1.427, B.1.429 and ancestral B.1 (614G) variants in hamsters. These results demonstrate enhanced virulence and high relative fitness of the epsilon (B.1.427/B.1.429) variant in Syrian hamsters compared to an ancestral B.1 (614G) strain. AUTHOR SUMMARY: In the last 12 months new variants of SARS-CoV-2 have arisen in the UK, South Africa, Brazil, India, and California. New SARS-CoV-2 variants will continue to emerge for the foreseeable future in the human population and the potential for these new variants to produce severe disease and evade vaccines needs to be understood. In this study, we used the hamster model to determine the epsilon (B.1.427/429) SARS-CoV-2 strains that emerged in California in late 2020 cause more severe disease and infected hamsters have higher viral loads in the upper respiratory tract compared to the prior B.1 (614G) strain. These findings are consistent with human clinical data and help explain the emergence and rapid spread of this strain in early 2021.

Identifiers

PMID34462750
PMCPMC8404898
OpenAlexW3194797006

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.